Skip to main content
main-content

24.09.2019 | Original Article – Cancer Research | Ausgabe 11/2019

Journal of Cancer Research and Clinical Oncology 11/2019

A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 11/2019
Autoren:
Lele Liu, Xingguo Song, Xinyi Li, Linlin Xue, Shanshan Ding, Limin Niu, Li Xie, Xianrang Song
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00432-019-03032-9) contains supplementary material, which is available to authorized users.
Lele Liu and Xingguo Song contributed equally to this work.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Background

During the development of tumors, tumors “educate” platelets causing changes in their mRNAs expression profiles and phenotypes, thereby, tumor-educated platelet (TEP) mRNA profile has the potential to diagnose lung cancer. The current study aimed to examine whether TEPs might be a potential biomarker for lung cancer diagnostics.

Methods

Platelet precipitation was obtained by low-speed centrifugation and subjected to Trizol for total RNA extraction. Platelet MAX, MTURN, and HLA-B mRNA were selected by microarray, validated by qPCR, and analyzed combined with related clinical factors.

Results

Our results showed that a three-platelet mRNA set: MAX, MTURN, and HLA-B was significantly up-regulated in lung cancer patients as well as in early-stage lung cancer patients compared with those from healthy donors, the area under the curve (AUC) was 0.734, 0.787, respectively, among which platelet MTURN mRNA processed a dramatically high diagnostic efficiency in female patients with lung cancer, its AUC for female was 0.825. More importantly, the three-platelet mRNA set: MAX, MTURN, and HLA-B was associated with chemotherapeutic effect, low mRNA expression of this three-platelet set was correlated with “favorable” first chemotherapy response.

Conclusions

A three-platelet mRNA set: MAX, MTURN and HLA-B enables blood-based lung cancer diagnosis and chemotherapy response prediction.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 Platelet quality control. Platelet purity was detected by wright-giemsa dye under a microscope (a), white arrow indicated the red blood cells, and activation state (b) of the platelet was detected by flow cytometry (TIFF 25418 kb)
432_2019_3032_MOESM1_ESM.tif
Supplementary material 2 Platelet UQCRH mRNA expression as biomarker for lung cancer. a Platelet UQCRH mRNA was elevated in lung cancer significantly. LC, patients with lung cancer; HD, healthy donors. b Low mRNA expression of UQCRH was correlated with favorable first chemotherapy response. PR, partial response. *P < 0.05. (TIFF 5418 kb)
432_2019_3032_MOESM2_ESM.tif
Supplementary material 3 (DOCX 31 kb)
432_2019_3032_MOESM3_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 11/2019

Journal of Cancer Research and Clinical Oncology 11/2019 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise